Status:
COMPLETED
Response of Clostridium Difficile Infection to Metronidazole Therapy
Lead Sponsor:
Michael E. DeBakey VA Medical Center
Collaborating Sponsors:
Baylor College of Medicine
Conditions:
Clostridium Enterocolitis
Pseudomembranous Colitis
Eligibility:
All Genders
18-64 years
Brief Summary
In this record review study, our objective is to determine the rates of cure, failure and relapse following treatment of C. difficile colitis with metronidazole.
Detailed Description
Clostridium difficile is a major cause of nosocomial infection. When this organism proliferates in the colon, usually as a result of prior antibiotic therapy in a hospitalized or otherwise debilitated...
Eligibility Criteria
Inclusion
- records of patients who have a fecal sample positive for C. difficile toxin and who are then treated for C. difficile colitis with oral metronidazole will be included in this study.
Exclusion
- Patients who did not receive at least 7 days of metronidazole
Key Trial Info
Start Date :
June 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2007
Estimated Enrollment :
290 Patients enrolled
Trial Details
Trial ID
NCT00304369
Start Date
June 1 2005
End Date
June 1 2007
Last Update
February 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Michael E. Debakey VA Medical Center
Houston, Texas, United States, 77030